Article Text

Download PDFPDF

1233 Reprogramming primary melanoma cells to dendritic cell fate enhances tumor immunogenicity
  1. Marta Velasco Santiago1,
  2. Olga Zimmermannova2,
  3. Morten Hansen1,
  4. Fabio Rosa3,
  5. Cristiana Pires3,
  6. Özcan Met1,
  7. Carlos-Filipe Pereira3 and
  8. Inge Marie Svane1
  1. 1National Center of Cancer Immune Therapy (CCIT-DK), Herlev, Denmark
  2. 2Molecular Medicine and Gene Therapy, Lund, Sweden
  3. 3Asgard Therapeutics, Lund, Sweden


Background Direct cell reprogramming is characterized by the use of defined factors to rewire the transcriptional and epigenetic network of one cell-type into one of a different lineage. We have recently identified the transcription factors PU.1, IRF8, and BAFT3 (PIB) as sufficient to induce a type 1 conventional dendritic cell (cDC1) fate in both somatic and cancer cells.1,2 cDC1 is a rare dendritic cell subset with unique ability to initiate de novo T cell responses after migrating to the tumor site. Several studies have shown that higher levels of cDC1s within the tumor microenvironment strongly correlate with good prognosis and responsiveness to immunotherapy for patients with melanoma.3 Therefore, we hypothesized that PIB factors could reprogram primary melanoma cells into functional antigen presenting cDC1s capable of presenting tumor antigens and restoring anti-tumor immunity.

Methods Primary melanoma cells from eight patients were reprogrammed into cDC1-like cells through transduction with lentivirus constitutively expressing PIB. Reprogrammed cells were profiled at multiple time-points to characterize reprogramming efficiency, phenotype, and functional properties including cytokine secretion and the capacity to prime T cells.

Results All eight PIB-transduced melanoma cells progressively acquired a cDC1 surface phenotype characterized by the expression of CD45 and HLA-DR, marking the acquisition of hematopoietic and antigen presentation phenotype. The cell reprogramming process was consistent across all cell lines. Induced cDC1s also expressed CD11c, the cDC1-specific markers CLEC9A and CD141 as well as the costimulatory molecules CD40, CD80 and CD86. Functionally, cDC1-like melanoma cells at day 9 secreted the human cDC1-specific cytokines IL12p70 and IL-29 upon stimulation with Poly(I:C). After pulsing with a 9mer MART-1 peptide restricted to HLA-A2, cDC1-like melanoma cells were able to prime allogeneic HLA-A2 matched naïve CD8+ T cells and resulted in expansion of MART-1-specific T-cells after an eight-day co-culture with IL-2 and IL-7. Moreover, autologous tumor-infiltrating lymphocytes (TILs) were more reactive (higher expression of CD107a, CD137, IFN-gamma, and TNF-alpha) and cytotoxic towards cDC1-like melanoma cells compared to the original tumor cells.

Conclusions Here, we demonstrated that melanoma cells from multiple patients can be efficiently reprogrammed into cDC1-like cells and present tumor-associated antigens. These results lay the groundwork for the development of cDC1 reprogramming as an innovative cancer immunotherapy to counteract immune escape and reactivating anti-tumor immunity.


  1. Rosa Fábio F, et al. Direct reprogramming of fibroblasts into antigen-presenting dendritic cells. Science Immunology. 2018;3(30):eaau4292.

  2. Rosa Fábio F, et al. Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells. Science Immunology. 2022;7(69):eabg5539.

  3. Tucci Marco, et al. Immune system evasion as hallmark of melanoma progression: the role of dendritic cells. Frontiers in Oncology. 2019;9:1148.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.